Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities

被引:22
|
作者
Meyers, Kathrine [1 ]
Golub, Sarit A. [2 ]
机构
[1] Aaron Diamond AIDS Res Ctr, New York, NY USA
[2] CUNY Hunter Coll, New York, NY 10065 USA
关键词
HIV prevention; implementation; long-acting antiretrovirals; preexposure prophylaxis; sociobehavioral research; PREEXPOSURE PROPHYLAXIS PREP; UNINTENDED PREGNANCY; ATTITUDES; RISK; TRIALS; PERCEPTION; ADHERENCE; KNOWLEDGE; SEX;
D O I
10.1097/COH.0000000000000159
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewBroad-based access, uptake, and dissemination of daily oral HIV preexposure prophylaxis (PrEP) have been slow, despite strong evidence for efficacy. Effective and efficient implementation of long-acting HIV prevention products will require both analysis of the dynamics and determinants of daily oral PrEP implementation and identification of the distinct challenges and opportunities inherent in emerging technologies.Recent findingsEvidence suggests the importance of addressing implementation issues at three levels: patient, provider, and system. Patient-level factors include targeted education and messaging, tailored supports to enhance acceptability and uptake, and effective strategies for promoting adherence/persistence and retention in care. Provider-level factors include engaging a broad mix of providers, while ensuring adequate training and support for patient assessment, counseling, and follow-up. Systems-level factors include optimal delivery modalities, resource allocation, and ensuring access to populations most in need of new prevention options.SummaryFormative social/behavioral research must be undertaken proactively to prepare for and address future implementation challenges and reduce the gap between proving efficacy in clinical trials and assuring real-world effectiveness. Conceptualizing new HIV prevention technologies as behavioral interventions at the level of the patient, provider, and system will be paramount to effective and efficient implementation.
引用
收藏
页码:290 / 295
页数:6
相关论文
共 50 条
  • [31] Challenges and opportunities in the development of complex generic long-acting injectable drug products
    O'Brien, Matthew N.
    Jiang, Wenlei
    Wang, Yan
    Loffredo, David M.
    JOURNAL OF CONTROLLED RELEASE, 2021, 336 : 144 - 158
  • [32] Challenges and opportunities in the development of complex generic long-acting injectable drug products
    O'Brien, Matthew N.
    Jiang, Wenlei
    Wang, Yan
    Loffredo, David M.
    Journal of Controlled Release, 2021, 336 : 144 - 158
  • [33] Towards long-acting HIV inhibitors
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2019, 18 (11) : 826 - 826
  • [34] Long-acting shot against HIV
    Wolf E.
    Noe S.
    MMW - Fortschritte der Medizin, 2017, 159 (Suppl 2) : 36 - 38
  • [35] Advancing use of long-acting and extended delivery HIV prevention and treatment regimens
    Delany-Moretlwe, Sinead
    Flexner, Charles
    Bauermeister, Jose A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [36] Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon, Geoffroy
    Ghosn, Jade
    HIV MEDICINE, 2023, 24 (06) : 653 - 663
  • [37] Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
    Krovi, Sai Archana
    Johnson, Leah M.
    Luecke, Ellen
    Achilles, Sharon L.
    van der Straten, Ariane
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 176
  • [38] The future of PrEP: novel long-acting HIV prevention agents for adolescent women
    Owuor, Sharon
    Kimani, Makobu
    Kaplan, Richard
    PAN AFRICAN MEDICAL JOURNAL, 2024, 47
  • [39] A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Pre-Exposure Prophylaxis for HIV Prevention
    Pilgrim, Nanlesta A.
    Evans, Tammeka M.
    Czarnogorski, Maggie
    HEALTH PROMOTION PRACTICE, 2022, 23 (06) : 912 - 915
  • [40] Prevention of Catatonia With Olanzapine Long-Acting Injectable
    Ifteni, Petru-Iulian
    Teodorescu, Andreea
    AMERICAN JOURNAL OF THERAPEUTICS, 2017, 24 (05) : E599 - E601